

REMINDER
NEW YORK PHARMA FORUM PROGRAM
MONDAY, JANUARY 29, 2001

SPEAKER: **Dr. David C. U'Prichard**
Chief Executive Officer
3-Dimensional Pharmaceuticals, Inc.

TOPIC: **“Lead Generation and Target Validation Bottlenecks in Post-Genomics Drug Discovery: How to Manage for Success”**

Dr. U'Prichard came to his current position at 3-Dimensional Pharmaceuticals a little over a year ago from SmithKline Beecham. While at SmithKline Beecham, Dr. Pritchard instituted a major reorganization of the 5,000-member research and development function to rebalance the focus toward the commercial needs of the company. Among his many activities at SmithKline Beecham, he oversaw the entry of 10 compounds into clinical development, and moved Avandia, the blockbuster diabetes drug, from clinical development to NDA filing.

His background in R&D management prior to SmithKline Beecham was at Zeneca, and he was also instrumental earlier in the launch of Nova Pharmaceuticals. Dr. U'Prichard has had academic tenure as Associate Professor of Pharmacology and Neurobiology at Northwestern University and also held faculty appointments at Johns Hopkins University, University of Maryland, and the University of Pennsylvania, and is an honorary professor at the University of Glasgow, Scotland.